

Our Ref: FOI ID 47908

16 May 2018

southportandformbyccg.foi@nhs.net

NHS Southport & Formby CCG
5 Curzon Road
Southport
PR8 6PL

Tel : 0151 317 8456

Email: southportandformby.ccg@nhs.net

Re: Freedom of Information Request

Please find below the response to your recent Freedom of Information request regarding use of rituximab within NHS Southport and Formby CCG.

Request/Response:

1. Do you have local clinical pathways or standard operating procedures (SOPs) for the use of MabThera? If so are you able to share these? For instance, is one cycle of MabThera intravenous (IV) always used before initiating the patients on MabThera subcutaneous (SC) in oncology indications?
2. Number of patients treated* using MabThera subcutaneous versus MabThera intravenous in oncology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:
3. Total number of patients treated* with MabThera (intravenous and subcutaneous) vs Rixathon vs Truxima in oncology and rheumatology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:
4. Do you have local clinical pathways or standard operating procedures (SOPs) for the initiation of new patient treatment regimens? If so are you able to share these?
5. Specifically, are new patients directly prescribed biosimilar rituximab (i.e. Truxima or Rixathon) instead of MabThera?
6. Are existing patients being switched from MabThera intravenous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?
7. Are any existing patients being switched from MabThera subcutaneous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?

8. Number of patients treated* using rituximab biosimilars (Truxima and Rixathon) instead of MabThera (intravenous and subcutaneous) between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:
9. As an organisation, are you aware of any financial savings made by using biosimilar rituximab (i.e. Truxima or Rixathon) vs MabThera between 2017-2018, if only partial data is available please indicate the timeframe the data refers to and the methods used to calculate the financial savings.
10. Please provide information for the current contracts for Truxima, Rixathon, MabThera intravenous (IV) or subcutaneous (SC):
11. Related to question 10, if contracts are tiered by volume, could you please provide the thresholds for each tier and what is the price percentage difference between tiers?

For questions 1-11 –

Oncology treatment with rituximab is commissioned by NHS England therefore you may wish to redirect your query.

NHS England.
england.contactus@nhs.net

The NHS Southport and Formby CCG commissioned pathway for rheumatology for rituximab can be found at –
<http://www.panmerseyapc.nhs.uk/recommendations/documents/PS134.pdf?UNLID=63204444201842314615>

Those questions relating to SOPs, patient numbers, savings made and contracts NHS Southport and Formby CCG do not hold this information, you may wish to refer your query to –

Southport & Ormskirk Hospital NHS Trust
soh-tr.foi@nhs.net



Southport and Formby
Clinical Commissioning Group